TER-2013 / Terremoto Biosciences - LARVOL DELTA

Terremoto Biosciences…announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for TER-2013, the Company’s lead AKT1-selective inhibitor, in patients with locally advanced, unresectable or metastatic HR+/HER2- breast cancer harboring one or more AKT/PI3K/PTEN alterations following progression on at least one endocrine-based therapy and CDK4/6 inhibitor (Terremoto Press release) - "TER-2013 is being evaluated in a Phase 1 clinical trial (NCT-07109726) in patients with solid tumors harboring AKT/PI3K/PTEN pathway alterations."

Fast track • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer